Finerenone and cardiorenal outcomes in diabetic kidney disease: a systematic review and meta-analysis of randomized controlled trial evidence
Among patients with type 2 diabetes (T2D), diabetic kidney disease (DKD) ranks among the foremost drivers of end-stage kidney disease and cardiovascular illness. Finerenone, a selective, nonsteroidal antagonist of the mineralocorticoid receptor, has been positioned as an agent that protects both heart and kidney. This...